ozempic versus semaglutide vs. Wegovy vs. Mounjaro: What's the Difference? This is what happens when

Wellner VP et al

Other complications can lead to permanent injuries and even debilitating ones

May foster a healthier gut microbiota environment

Eli Lilly and Companys #Triple #Agonist #Retatrutide #Delivers #Powerful #Weight #Loss in Pivotal Phase 3 TRIUMPH-1 Obesity Trial 28.3% #Weight #Loss (70.3 lbs), 45.3% Achieve 30% Reduction, Approaching Bariatric Surgery-Level Outcomes Eli Lilly and Company just reported powerful Phase 3 TRIUMPH-1 topline data for retatrutide, its investigational triple agonist (GIP/GLP-1/glucagon) obesity therapy and the numbers may redefine expectations in obesity medicine

Den Besten G, Bleeker A, Gerding A, Van Eunen K, Havinga R, Van Dijk TH, et al

Half-life ~6 days in human pharmacokinetic studies, supporting once-weekly dosing in trial protocols